Anti-CAPS-2 Antibody

CAPS-2 and the related protein CAPS-1 encode novel neural/endocrine-specific cytosolic and peripheral membrane proteins. Both are essential components of the synaptic vesicle priming machinery and are required for the Ca2+-regulated exocytosis of secretory vesicles; CAPS-deficient neurons contain no or very few fusion competent synaptic vesicles, causing a selective impairment of fast phasic transmitter release. Like CAPS-1, numerous isoforms of CAPS-2 are known to exist. These isoforms show distinct expression patterns in the brain. For example, CAPS2b showed high expression in the developing cerebellum. Furthermore, one version of CAPS-2 mRNA that lacks exon 3 is detected in some autistic patients, suggesting that the differential expression pattern of CAPS-2 is involved in neuronal development.

This antibody is predicted to be specific to CAPS-2 and not recognize CAPS-1.

KLH-conjugated linear peptide corresponding to human CAPS-2.

Anti-CAPS-2 detects levels of CAPS-2 proteins & has been published & validated for use in WB & IHC.

Western Blot Analysis: 1 µg/mL from a representative lot detected CAPS-2 in 10 µg/mL of human brain tissue lysate.

Immunohistochemistry Analysis: A 1:2,000 dilution from a representative lot detected CAPS-2 in rat cerebellum tissue.

Evaluated by Western Blot in mouse brain tissue lysate.

Western Blot Analysis: 1 µg/mL of this antibody detected CAPS-2 in 10 µg/mL of mouse brain tissue lysate.

~160 kDa observed. Uncharacterized bands may appear at ~40 kDa, ~50 kDa, and ~210 kDa in some lysates.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.